Bristol-Myers partners with Parker Institute, CRI on a next-gen twist on translational R&D
Bristol-Myers Squibb is teaming up with the growing virtual network of scientists at the Parker Institute for Cancer Immunotherapy to expand its focus on an already thick pipeline of immuno-oncology programs.
The 300-plus scientists who make up the Parker Institute — the nonprofit set up by Facebook mogul Sean Parker — will now see their proverbial toolbox grow as Bristol-Myers kicks in on a three-way pact that also includes the Cancer Research Institute. And a top researcher at Parker says that this is just the first of many such industry collaborations, as Parker’s group looks to ramp up translational work on a range of new cancer drugs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
